Skip to main content

Call for papers - Neurogenomics: from the bench to the clinic

Guest Editors

Daniel Geschwind, MD, PhD, UCLA Brain Research Institute, USA
Jessica Rexach, MD, PhD, UCLA Brain Research Institute, USA

Submission Status: Open   |   Submission Deadline: 2 September 2025

Genome Medicine is calling for submissions to a new Collection on the interpretation and application of genetic and genomic variation in the prevention, diagnosis, and treatment of neurological disorders, guest edited by Daniel Geschwind and Dr Jessica Rexach. 



New Content ItemThis Collection supports and amplifies research related to SDG 3: Good Health & Well-Being.

About the Collection

Genome Medicine is pleased to present the Collection "Neurogenomics, from the bench to the clinic”. This issue will capture advances in the interpretation and application of genomic technologies and the understanding of genetic variation in the prevention, diagnosis and treatment of brain disorders, with a focus on neurodevelopmental, neuropsychiatric and neurodegenerative diseases. Of particular interest will be issues informing ancestral diversity in research and practice; advances in application of genomic technologies, such as single cell genomics, genetic and genomic biomarkers; the clinical utility of novel risk factors, including polygenic scores and the design of novel therapies; as well as the use of genetic and genomic profiling in clinical trial recruitment and monitoring the effects of treatment in trials.

In this Collection, guest edited by Dr Daniel Geschwind and Dr Jessica Rexach, we aim to highlight the advances in understanding disease pathophysiology that can inform how neurological and neuropsychiatric disorders are diagnosed and treated. We are inviting the submission of Research, Method, Software and Guideline manuscripts with significant clinical or translational impact, in all areas of neurological disease, including:

  • Genetic and clinical heterogeneity
  • Ancestry diversity
  • Multimodal analyses in patient tissue and in clinical management, including single nucleus, single-cell, lrWGS
  • Practice challenges for implementing clinical practices of genetic testing in clinical practice (such as variable insurance coverage for clinical genetic testing)
  • Human model systems, including IPSC and humanized mice
  • Drug discovery and therapies
  • Clinical trials
  • Precision medicine
  • Community-driven data-sharing 


We encourage work that fosters collaboration among scientists from multi-disciplinary fields and academic-industry partnerships.

Image credit: ©SciePro / stock.adobe.com

Meet the Guest Editors

Back to top

Daniel Geschwind, MD, PhD, UCLA Brain Research Institute, USA

Dr Geschwind is the Gordon and Virginia MacDonald Distinguished Professor of Neurology, Psychiatry and Human Genetics at UCLA. In his capacity as Senior Associate Dean and Associate Vice Chancellor of Precision Health, he leads the Institute for Precision Health (IPH) at UCLA. In his laboratory, his group has pioneered the application of systems biology methods in neurologic and psychiatric disease, with a focus on autism spectrum disorders (ASD) and neurodegenerative conditions. His laboratory has made major contributions to identifying genetic causes of autism spectrum disorder, defining the molecular pathology of autism and allied psychiatric disorders, and has worked to increase diversity in autism research. His work in dementia is focused on the mechanisms of tauopathies, where his laboratory is developing novel therapeutic approaches. He sits on editorial boards of Cell, Science and Neuron, and is among the highest cited neurologists in the world. He has received several awards for his laboratory’s work including the American Neurological Association (ANA) Derek Denny-Brown Neurological Scholar Award, most recently the Society of Biological Psychiatry Gold Medal Award and the American Academy of Neurology’s 2022 Cotzias Lecture and Award. He is the 2022 National Academy of Medicine recipient of the Rhoda and Bernard Sarnat International Prize in Mental Health. He is an elected Member of the American Association of Physicians and the National Academy of Medicine.

Jessica Rexach, MD, PhD, UCLA Brain Research Institute, USA

Dr Jessica Rexach is currently a physician-scientist and Assistant Professor in the UCLA Neurogenetics Program with clinical specialty in neurodegenerative disorders affecting cognition and dementia. She completed her postdoctoral research training in the laboratory of Dr Daniel Geschwind. Dr Rexach’s research uses human genetics and systems biology to understand immune signaling in Alzheimer’s and associated dementias with the goal of developing immune-targeted therapies. Dr Rexach earned her BA degree in Chemistry and Biology at Cornell University in 2003. She subsequently entered the joint MD-PhD program between California Institute of Technology and University of California, Los Angeles (UCLA), completing her medical degree and doctoral degrees in Neuroscience (with a research focus in Chemical Biology) in 2012. Her graduate work resulted in three first author publications in Nature Chemical Biology. She completed a medical internship at Cedars-Sinai Medical Center and a residency in Neurology at UCLA. She subsequently completed a competitive National Institutes of Health-sponsored joint research and clinical fellowship in Neurogenetics and Neurobehavior at UCLA. Throughout her education and training, Dr Rexach has been recognized for excellence in teaching, clinical care, and science. She has received numerous awards including the August Rose Award for Excellence in Teaching and the Jean-Louis Riehl Research Award from the UCLA Department of Neurology, the Leo G. Rigler Award for Outstanding Achievement as a medical intern from Cedars-Sinai Medical Center, the Emil Bogen Research Prize from the David Geffen School of Medicine at UCLA, the Leo and Berdie Mandelkern Prize in Chemistry from Cornell University, and in 2018, the John Douglas French Alzheimer’s Foundation Research award. 
 

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of original Research, Method, Software, and Guideline Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Neurogenomics in the clinic" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.